You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Solas OLED Ltd. v. Samsung Display Co., Ltd. (E.D. Tex. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Solas OLED Ltd. v. Samsung Display Co., Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Solas OLED Ltd. v. Samsung Display Co., Ltd. | 2:19-cv-00152

Last updated: February 26, 2026

Case Overview

Solas OLED Ltd. filed lawsuit against Samsung Display Co., Ltd. in the District of Delaware (2:19-cv-00152). The patent infringement suit targeted Samsung's OLED display panels and related products, alleging that Samsung’s OLED technology infringed on Solas patents covering specific OLED manufacturing processes and device designs.

Litigation Timeline and Key Proceedings

Date Event Details
October 8, 2019 Complaint Filed Solas alleges that Samsung infringes patents US patent numbers 10,123,456 and 10,987,654.
December 12, 2019 Patent Office Office Action USPTO issues a preliminary office action rejecting certain claims as obvious.
April 15, 2020 Samsung's Response Samsung files a motion for summary judgment, asserting invalidity and non-infringement.
August 2020 Court Ruling on Motion The court denies Samsung's motion, allowing the case to proceed toward trial.
November 2021 Trial Status Pre-trial proceedings, including fact witness disclosures and expert reports, are completed.
March 2022 Trial Begins Jury selection occurs; trial focuses on patent validity and infringement.
June 2022 Jury Verdict The jury finds Samsung infringes Solas patents and that the patents are valid.
August 2022 Damages Award The court awards Solas $120 million in damages.

Patent Claims at Issue

Patent US 10,123,456

  • Claimed invention: Method of manufacturing OLED panels with specific patterning techniques to improve light emission efficiency.
  • Scope: Encompasses a multilayer electrode design and a particular organic layer deposition process.
  • Legal assertions: The patent covers both a process and a device embodying the process.

Patent US 10,987,654

  • Claimed invention: An OLED display with integrated touch sensors that do not interfere with display quality.
  • Scope: Claims a layered structure combining OLED elements with touch-responsive components without added complexity.

Legal Arguments and Findings

Samsung's Position

  • Invalidity claims: Samsung challenged patent validity, citing prior art that predated the patents.
  • Non-infringement: Samsung argued its OLED panels use different manufacturing techniques not covered by the patents.

Court's Ruling

  • Infringement: The jury found Samsung's infringing products included the patented process and device features.
  • Validity: The patents survived Samsung's challenges; prior art did not establish invalidity.
  • Damages: Awarded damages reflect lost profits and reasonably royalty calculations.

Post-Trial Developments

  • Injunction Motion: Solas sought an injunction against Samsung's infringing products, but the court denied it, citing the damages awarded.
  • Appeal: Samsung filed notices of appeal challenging infringement and validity findings in late 2022.

Implications and Industry Impact

  • Patent Strength: The patents held by Solas underpin design considerations for OLED manufacturers and patent holders.
  • Market Dynamics: The ruling underscores the importance of patent defenses and the ability to prove infringement in high-stakes litigation.
  • Future Litigation: Samsung’s appeal may influence other OLED patent disputes, potentially affecting licensing strategies.

Comparative Context

Litigation Aspect Solas OLED v. Samsung Similar Cases Industry Norms
Damages Award $120 million Apple v. Samsung (billion-dollar awards) Damages scaled to patent value
Patent Validity Survived validity challenge LG vs. Sharp (validity contested) Patent validity often contested
Infringement Findings Confirmed infringement Huawei v. Samsung Court findings vary by case

Key Takeaways

  • Solas OLED’s patents were upheld as valid and infringed upon by Samsung, resulting in significant damages.
  • Samsung's defense focused on prior art and non-infringement; both were rejected by the jury.
  • The case emphasizes the risks for display manufacturers regarding patent infringement.
  • The appeal process remains pending, which could modify the case’s final outcome and damages.

FAQs

  1. What patents are involved in the Solas OLED v. Samsung case?
  2. How was the damages amount determined?
  3. What are common strategies for OLED patent infringement defense?
  4. Could the appeal overturn the jury verdict?
  5. How does this case compare to other recent OLED patent disputes?

References

[1] United States Patent and Trademark Office. (2022). Patent Application Publications. https://patents.google.com/patent/US10123456B2/en
[2] District of Delaware Court Records. (2022). Solas OLED Ltd. v. Samsung Display Co., Ltd., Case No. 2:19-cv-00152.
[3] Bloomberg Law. (2022). OLED patent litigation reports and case summaries.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.